Gilead Sciences stock gains 2.57 percent after AI agreement expands

Published on 10/07/2026 at 16:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock was trading at USD 147.94 on October 7, 2026, up 2.57 percent as a five-year technology deal took shape. Q2 HIV sales rose 12 percent.

Bauhaus-Poster BIOTECH mit geometrischen Formen und Primärfarben für Gilead Sciences — Gilead Sciences Bauhaus-Poster ISIN US3755581036 geometrisch BIOTECH Primärfarben Konstruktivismus medizinisches Kreuz Design, Illustration mit AI erstellt.

Gilead Sciences stock (ISIN US3755581036) was trading at USD 147.94 on Nasdaq on October 7, 2026, up 2.57 percent from USD 144.23. The move came as BioSpace reported on October 6 that Cognizant had agreed to extend its work with Gilead for five years, including support for DevOps and agentic AI tools.

Five-year technology agreement

The agreement expands a relationship that has lasted more than a decade and covers selected technology programs rather than a disclosed product or licensing transaction. The work is intended to support Gilead's development and operations environment, with practical applications for process improvement and program execution, according to BioSpace.

The agreement gives the market a current operational detail, but Gilead's investment case remains tied to its medicines portfolio. The latest quarter showed revenue of USD 7.803 billion in Q2 2026, compared with USD 6.960 billion in Q1 2026, while the company reported a Q2 net loss of USD 10.496 billion and diluted EPS of negative USD 8.45.

HIV growth offsets accounting pressure

In the Q2 2026 earnings call, Yahoo Finance reported that HIV sales rose 12 percent year over year to USD 5.7 billion. Quarterly PrEP sales exceeded USD 1 billion for the first time, and management raised full-year 2026 HIV growth guidance to 9 percent to 10 percent from 8 percent.

The contrast is important for investors: operating demand improved while acquisition-related charges weighed on reported earnings. Gilead's Q2 operating performance included gross profit of USD 6.224 billion and operating cash flow of USD 3.573 billion, figures that point to a stronger underlying business than the headline net loss alone suggests.

Management also guided to 2026 total product sales of USD 30.1 billion to USD 30.4 billion. The same earnings call put base-business sales guidance at USD 29.8 billion to USD 30.1 billion and identified cell therapy as a business expected to decline in the mid-teens percentage range.

Consensus target remains above price

According to MarketBeat on October 5, 2026, 23 analysts rated Gilead Buy and six rated it Hold, producing a Moderate Buy consensus and an average price target of USD 158.78. That target lies 7.33 percent above the Nasdaq price of USD 147.94.

The counterweight is analyst dispersion and the cost of expansion. MarketBeat reported that Zacks Research cut its rating from strong buy to Hold on October 1, while the broader consensus stayed Moderate Buy.

Stock trades below yearly high

Gilead Sciences stock was last at USD 147.94 on Nasdaq on October 7, 2026 at 9:58 a.m. ET. The session range was USD 144.53 to USD 148.60, and the 52-week range was USD 93.37 to USD 157.29.